The past three decades have borne witness to many advances in the understanding of the
molecular biology and treatment of nasopharyngeal carcinoma (NPC), an Epstein–Barr virus …

Epidemiological trends during the past decade suggest that although incidence of
nasopharyngeal carcinoma is gradually declining, even in endemic regions, mortality from …

The heterogeneous nature of tumour microenvironment (TME) underlying diverse treatment
responses remains unclear in nasopharyngeal carcinoma (NPC). Here, we profile 176,447 …

The NCCN Guidelines for Head and Neck (H&N) Cancers provide treatment
recommendations for cancers of the lip, oral cavity, pharynx, larynx, ethmoid and maxillary …

Purpose This multinational study evaluated the antitumor activity of nivolumab in
nasopharyngeal carcinoma (NPC). Tumor and plasma-based biomarkers were investigated …

Nasopharyngeal carcinoma (NPC) is closely associated with Epstein-Barr virus (EBV) and
occurs frequently in the south of China and Southeast Asian countries. Concurrent chemo …

PURPOSE GEM20110714 (ClinicalTrials. gov identifier: NCT01528618), the first
randomized, phase III study of systemic chemotherapy in recurrent or metastatic …

Purpose The Intergroup 00-99 Trial for nasopharyngeal cancer (NPC) showed a benefit of
adding chemotherapy to radiotherapy. However, there were controversies regarding the …

Background MicroRNAs (miRNAs) can be used as prognostic biomarkers in many types of
cancer. We aimed to identify miRNAs that were prognostic in patients with nasopharyngeal …

Epstein–Barr virus-associated diseases are important global health concerns. As a group I
carcinogen, EBV accounts for 1.5% of human malignances, including both epithelial-and …